Which Vascular Specialists Are Performing Tibial Atherectomies And Angioplasties For Intermittent Claudication And Are There Suboptimal Outcomes: Is Atherectomy Usage Overall Being Abused

Update On Atherectomy Devices: Do They Still Have A Role In 2024: Which One Or Ones Are Best: Has Their Benefit Been Proven

Atherectomy In Patients With CLTI, In Stent Restenosis (ISR) And Diabetes: When Is It Helpful; How Durable Is It: Which Devices Are The Best

The Objective Benefits Of Directional Atherectomy In Treating Lower Extremity Occlusive Lesions Are Real: When And How Should It Be Used And When Should It Not

What Is The Evidence That Atherectomy Is Effective In Femoropopliteal Interventions

For BTK Lesions, Results Justify A Change In The Role Of Stenting From Bailout Use To Primary Stenting: For Which Lesions And With Which Stents

An Update Of The 2-Year Results And Economic Cost Effectiveness Analysis Of The LIFE-BTK Randomized Controlled Comparison Of Abbott’s Esprit Drug-Eluting Resorbable Stent (DERS) With Plain Old Balloon Angioplasty (POBA): When Will DERSs Make A Difference

Update On Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5 Years: From The DISAPEAR Registry And A Meta-Analysis Of Other Bioresorbable BTK Stent Results

Updated Experience With Everolimus And Other Nonabsorbable DESs To Treat Infrapopliteal BTK Lesions – Long And Short – Causing CLTI: What Are The Stents And When Do They Help: Why Will The DERSs Be Better

Late-Breaking Final Patency And Wound Healing Results With A 3-French Compatible Microstent (From Micro Medical) Versus POBA For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: From The STAND RCT

Panel Discussion